A Patient's Ordeal: The Enduring Battle with Antidepressant Withdrawal

This narrative chronicles a challenging journey through antidepressant withdrawal, revealing the profound and often incapacitating effects that can emerge even after years of careful tapering. The author's personal experience with Cymbalta underscores the unpredictable and severe nature of discontinuing psychiatric medications, particularly the re-emergence of akathisia and its devastating impact on daily life. This account highlights the critical need for comprehensive understanding and support for individuals navigating the complexities of psychiatric drug cessation.

The author, a licensed clinical social worker, previously shared insights from her role as a moderator for an antidepressant taper support group. She noted that despite nearly two decades in a psychiatric hospital, the concept of withdrawal was rarely discussed. This lack of awareness starkly contrasted with her personal ordeal when attempting to discontinue Cymbalta.

In 2019, an eight-month taper from 60 mg led to severe akathisia, a condition characterized by extreme physical restlessness and intense internal terror. This was so debilitating that she contemplated ending her life. Reinstating the medication provided relief, allowing her to embark on a much slower tapering process from 30 mg, which she believed would be successful.

After a painstaking 12-month reduction of the remaining micro-beads, and a further six months holding the lowest dose, she successfully ceased the medication. Four months later, unexpected emotional overwhelming triggered by a simple act of kindness served as a precursor to the return of akathisia. Recognizing this as a critical warning sign from her previous experience, she cautiously reinstated a single micro-bead.

Despite this preventive measure, the akathisia returned with full force. Symptoms included sudden jolts during sleep, an internal tremor, loss of appetite, a burning sensation in her arms (paresthesia), and a terrifying internal fire accompanied by dread and a racing heart rate of 160 bpm. These sensations left her feeling like a fragile boat in a storm, clinging to sanity.

Confused and desperate, she sought advice from tapering experts, who were unavailable. A moment of clarity led her to recall an interview with Dr. Stuart Shipko, a psychiatrist known for his views on antidepressant withdrawal. Dr. Shipko, when contacted, advised reinstating the full original dose of 60 mg, counter to common advice in support groups that advocated for low-dose reinstatement. He shared that he had seen successful reinstatements even years after discontinuation.

Empowered by his guidance, she increased her dose from 2.7 mg to 30 mg, then to 40 mg, which stabilized her condition. She expressed immense gratitude to Dr. Shipko, crediting him with saving her life. She acknowledged the difficulty and risks of reinstatement, where too much can worsen symptoms and too little can be ineffective. The initial increase in symptoms upon reinstatement was frightening, but the eventual subsiding of the burning sensation signaled improvement.

Her deep dive into antidepressant tapering and withdrawal over the past six years has revealed the potential for akathisia to last for years or become permanent. Given the severity of her symptoms, she is convinced that attempting to taper further would lead to years of debilitating suffering. This realization has led her to accept that she may never be able to fully discontinue antidepressants. The dependence extends to specific manufacturers, as illustrated by Eli Lilly's discontinuation of Cymbalta production, which for some like her, poses a crisis.

Akathisia presents differently for everyone. For her, profound fatigue was a significant and terrifying symptom, distinct from the fatigue she experiences with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), an illness she has managed for 18 years. The fatigue associated with akathisia was a crushing weight, making basic movement almost impossible, a state she vowed never to return to. This contrasted with the story of another individual who, after recovering from akathisia, developed a chronic and disabling central nervous system fatigue.

Research confirms that antidepressant withdrawal can persist for years and severely disrupt lives. While some successfully withdraw, others, like the author, are compelled to reinstate the medication due to unbearable withdrawal symptoms. Despite a five-year tapering effort, she remains dependent on Cymbalta. Although she experiences minimal side effects from the medication itself, she notes an increased appetite and carb cravings, leading to significant weight gain. She recognizes that this is a relatively minor side effect compared to the severe, debilitating side effects and tormenting withdrawal symptoms experienced by many others who are effectively trapped in a cycle of suffering.

The duration of medication use does not reliably predict withdrawal severity. The author learned from her moderator experience that even short-term use can lead to severe withdrawal. While she remains hopeful that a slow, controlled taper (no more than 10% reduction per month) can be successful for many, she feels it's crucial to share her story to highlight the very real risks, including the possibility that some individuals may never be able to fully stop the medication without suffering agonizing withdrawal. Ultimately, she has no regrets about attempting to taper, as it was the only way to discover her individual response, and for many, the attempt can indeed be successful.